

PATENT  
Customer No. 22,852  
Attorney Docket No.: 06478.1442  
Application Serial No.: 09/559,344

**AMENDMENTS TO THE CLAIMS:**

This listing of claims will replace all prior versions and listings of claims in the application:

1. (currently amended) A DNA-construct for the tissue-specific expression of a blood coagulation factor comprising a DNA sequence coding for an amino acid sequence of a blood coagulation factor and a DNA sequence functioning as a promoter which is specific for expression in megakaryocytes hematopoietic cells.
2. (currently amended) The DNA-construct as claimed in claim 18, wherein the DNA sequence functioning as a promoter is the DNA sequence for the human platelet glycoprotein IIb (GPIIb) promoter.
3. (currently amended) The DNA-construct as claimed in claim 18, wherein the blood coagulation factor is Factor IX.
4. (currently amended) The DNA-construct as claimed in claim 18, wherein a first truncated intron (Intron 1) of the human FIX gene is inserted into the DNA sequence coding for an amino acid sequence of a blood coagulation factor.

5-8. (canceled).

FINNEGAN  
HENDERSON  
FARABOW  
GARRETT &  
DUNNER LLP

1300 I Street, NW  
Washington, DC 20005  
202.408.4000  
Fax 202.408.4400  
[www.finnegan.com](http://www.finnegan.com)

PATENT  
Customer No. 22,852  
Attorney Docket No.: 06478.1442  
Application Serial No.: 09/559,344

9. (currently amended) A process for the production of a blood coagulation factor in a hematopoietic cell line comprising:

- transfecting hematopoietic cells with a DNA-construct

coding for a blood coagulation factor comprising:

- a DNA sequence coding for the amino acid

sequence of a blood coagulation factor, and

- a DNA sequence functioning as a promoter which is specific for expression in megakaryocytes

hematopoietic cells; and

- expressing the DNA-construct.

10. (previously presented) The process as claimed in claim 9, wherein the production of the blood coagulation factor is stimulated by an inducer.

11. (previously presented) The process as claimed in claim 10, wherein the inducer is phorbol-12-myristate-13-acetate (PMA).

12. (previously presented) The process according to claim 9 wherein the DNA sequence functioning as a promoter is the DNA sequence for the human platelet glycoprotein IIb (GPIIb) promoter.

13-14. (canceled).

FINNEGAN  
HENDERSON  
FARABOW  
GARRETT &  
DUNNER LLP

1300 I Street, NW  
Washington, DC 20005  
202.408.4000  
Fax 202.408.4400  
[www.finnegan.com](http://www.finnegan.com)

PATENT  
Customer No. 22,852  
Attorney Docket No.: 06478.1442  
Application Serial No.: 09/559,344

15. (new) The process according to claim 9, wherein the blood coagulation factor is Factor IX.

16. (new) The process according to claim 9, wherein a first truncated intron (Intron 1) of the human FIX gene is inserted into the DNA sequence coding for an amino acid sequence of a blood coagulation factor.

FINNEGAN  
HENDERSON  
FARABOW  
GARRETT &  
DUNNER LLP

1300 I Street, NW  
Washington, DC 20005  
202.408.4000  
Fax 202.408.4400  
[www.finnegan.com](http://www.finnegan.com)